manilatimes1 天
RESTEM Receives FDA Fast Track Designation for Restem-L for Idiopathic Inflammatory Myopathy
Recently reported Phase 1 data of Restem-L demonstrated a clinically meaningful efficacy and significant reduction in steroid ...
Pharmaceutical Technology2 天
YTS-109 by Bristar Immunotech Biotechnology for Polymyositis: Likelihood of Approval
YTS-109 is under clinical development by Bristar Immunotech Biotechnology and currently in Phase I for Polymyositis.
Pharmaceutical Technology3 天
ULSCs by RESTEM for Polymyositis: Likelihood of Approval
ULSCs is under clinical development by RESTEM and currently in Phase I for Polymyositis. According to GlobalData, Phase I drugs for Polymyositis does not have sufficient historical data to build an ...